Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
17.67
-0.23 (-1.28%)
Streaming Delayed Price
Updated: 2:28 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
May 15, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
May 09, 2024
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
Via
Benzinga
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
May 08, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
March 11, 2024
Via
Benzinga
Recap: Arcturus Therapeutics Q4 Earnings
March 07, 2024
Via
Benzinga
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
April 25, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023
March 07, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
March 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Earnings Preview: Arcturus Therapeutics
March 06, 2024
Via
Benzinga
Evaluating NASDAQ:ARCT for Growth Investment Opportunities.
February 27, 2024
High growth, ROE and beating expectations for NASDAQ:ARCT: growth investors may appreciate this.
Via
Chartmill
Is NASDAQ:ARCT suited for growth investing?
February 06, 2024
Is ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) suited for growth investing?
Via
Chartmill
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
February 26, 2024
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Via
InvestorPlace
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
February 26, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
February 22, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.
Via
InvestorPlace
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
February 20, 2024
We have researched tech stocks for you and have found these three are likely multibaggers in the making. Considering picking them up today.
Via
InvestorPlace
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
February 20, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
February 05, 2024
From
Arcturus Therapeutics
Via
Business Wire
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
January 23, 2024
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
January 16, 2024
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations
December 26, 2023
Exploring growth characteristics of ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
Via
Chartmill
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
December 21, 2023
From
Arcturus Therapeutics
Via
Business Wire
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Via
InvestorPlace
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
December 13, 2023
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.
Via
InvestorPlace
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
December 13, 2023
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.
Via
Benzinga
5 Value Stocks In The Healthcare Sector
December 04, 2023
Via
Benzinga
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 04, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Why the growth investor may take a look at NASDAQ:ARCT.
December 04, 2023
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.